Blueprint Medicines Corporation reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 71.96 million compared to USD 38.78 million a year ago. Net loss was USD 110.92 million compared to USD 158.64 million a year ago. Basic loss per share from continuing operations was USD 1.82 compared to USD 2.65 a year ago. Diluted loss per share from continuing operations was USD 1.82 compared to USD 2.65 a year ago.
For the full year, revenue was USD 249.38 million compared to USD 204.04 million a year ago. Net loss was USD 506.98 million compared to USD 557.52 million a year ago. Basic loss per share from continuing operations was USD 8.37 compared to USD 9.35 a year ago. Diluted loss per share from continuing operations was USD 8.37 compared to USD 9.35 a year ago.